We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II Study of UFT in Patients With Advanced Non-Small Cell Lung Cancer.
- Authors
KEICHO, NAOTO; SAIJO, NAGAHIRO; SHINKAI, TETSU; EGUCHI, KENJI; SASAKI, YASUTSUNA; TAMURA, TOMOHIDE; SAKURAI, MASANORI; SANO, TETSURO; HOSHI, AKIO
- Abstract
A phase II study of UFT (a mixture of uracil and tegafur; molar ratio of uracil to tegafur = 4) was undertaken in 21 patients with advanced non-small cell lung cancer (NSCLC). UFT was administered orally at a dose of 400 mg/m2 every day, for more than four weeks.Of 16 adequately treated patients, one (6.3%) showed a partial response. Toxic effects included minimal myelosuppression, anorexia, nausea, vomiting and epigastralgia. Gastrointestinal toxicity was well tolerated. Considering the poor response and mild toxicity, a further phase II study of higher-dose UFT is necessary for patients without prior therapy.
- Publication
Japanese Journal of Clinical Oncology, 1986, Vol 16, Issue 2, p143
- ISSN
0368-2811
- Publication type
Article